What are immune checkpoint inhibitors?
Immune checkpoint inhibitors are a type of immunotherapy. They are medicines that release the brakes on the immune system, so that it can recognise and attack cancer cells more effectively. They are given as a drip into a vein, usually every few weeks.
The immune system has built-in “checkpoints”, which are signals that stop immune cells from attacking the body’s own tissues. Many cancers exploit these checkpoints to hide from the immune system. Checkpoint inhibitors block these signals and let T cells (white blood cells that fight infection and cancer) do their job.
These drugs have changed the outlook for several cancers that were once very hard to treat, including advanced melanoma, lung cancer and kidney cancer. Some people treated with them remain well for many years. However, they do not work for everyone, and they can cause unusual side effects when the immune system attacks healthy organs.
The main types
| Target | How it works | Examples of drugs |
|---|---|---|
| PD-1 | Blocks a brake receptor on T cells | Nivolumab, pembrolizumab, cemiplimab, dostarlimab |
| PD-L1 | Blocks the partner molecule that tumours use to switch off T cells | Atezolizumab, durvalumab, avelumab |
| CTLA-4 | Blocks an early brake that limits T cell activation in lymph nodes | Ipilimumab, tremelimumab |
| LAG-3 | Blocks another brake on T cells, used with a PD-1 drug | Relatlimab |
A brief history
Scientists discovered CTLA-4 and PD-1 in the 1980s and 1990s while studying how the immune system avoids attacking healthy tissue. James Allison and Tasuku Honjo showed that blocking these brakes could make tumours shrink in laboratory models, work that earned them the Nobel Prize in 2018. Ipilimumab became the first approved checkpoint inhibitor in 2011, followed by the first PD-1 drugs in 2014.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of treatment | Immunotherapy (monoclonal antibodies) |
| Main uses | Melanoma, lung, kidney, bladder, head and neck cancers, and many more |
| How it is given | Drip into a vein over 30-60 minutes; some drugs now under the skin |
| Frequency | Every 2, 3, 4 or 6 weeks, depending on the drug |
| Course length | Often up to 1-2 years, or less after surgery |
| Used with | Alone, in pairs, or with chemotherapy or targeted therapy |
| Common side effects | Tiredness, rash, itching, diarrhoea, thyroid problems |
| Serious side effects | Inflammation of the bowel, lungs, liver, hormone glands, heart or other organs |
2. How it works
The immune brakes
| Checkpoint | Normal job | What happens in cancer | What the drug does |
|---|---|---|---|
| CTLA-4 | Limits T cell activation at an early stage, mainly in lymph nodes | Keeps the immune response weak from the start | Lets more T cells become active against the cancer |
| PD-1 / PD-L1 | Switches off T cells in tissues to prevent damage | Tumours display PD-L1 to turn off T cells that reach them | Lets T cells inside the tumour keep attacking |
Because the drugs act on the immune system rather than directly on the cancer, responses can take longer to appear than with chemotherapy. Occasionally, tumours look bigger on early scans because immune cells move in, before they shrink. This is called pseudoprogression, though it is uncommon.
Markers that help predict response
| Marker | Meaning |
|---|---|
| PD-L1 level | Higher levels on tumour cells often predict a better chance of response in lung cancer and some other cancers |
| Mismatch repair deficiency (dMMR) or MSI-high | Tumours with many mutations are more visible to the immune system |
| Tumour mutational burden | A higher number of mutations may predict benefit |
3. Who it is for
Conditions treated
| Condition | Typical role |
|---|---|
| Melanoma | Advanced disease and after surgery for higher-risk melanoma |
| Non-small cell lung cancer | Advanced disease, with or without chemotherapy; also around surgery and after chemoradiotherapy |
| Small cell lung cancer | Added to chemotherapy for extensive stage |
| Clear cell renal cell carcinoma | Advanced disease, often combined with another drug |
| Urothelial carcinoma of the bladder | Advanced disease and after surgery in some people |
| Merkel cell carcinoma | Advanced disease |
| Cutaneous squamous cell carcinoma | Advanced disease not suitable for surgery or radiotherapy |
| Hodgkin lymphoma | Relapsed disease, and increasingly in first-line treatment |
| Hepatocellular carcinoma | Advanced disease, often with another drug |
| Triple-negative breast cancer | With chemotherapy before and after surgery, and in advanced disease |
| Colorectal adenocarcinoma | Tumours with mismatch repair deficiency |
| Endometrial cancer | With chemotherapy, especially for mismatch repair-deficient tumours |
| Malignant pleural mesothelioma | Combination immunotherapy for advanced disease |
Who may need extra caution
| Situation | Reason |
|---|---|
| Active autoimmune disease | Such as severe Crohn’s disease or lupus, which may flare |
| Organ transplant | Risk of rejection |
| High-dose steroids | May reduce the effect of treatment |
| Very poor general health | Benefit is less likely |
4. Before treatment
| Step | Why it is done |
|---|---|
| Tumour testing | PD-L1, mismatch repair or other markers, depending on the cancer |
| Blood tests | Baseline thyroid, liver, kidney, blood sugar and cortisol levels |
| Scans | To measure the cancer before treatment |
| Medical history | Autoimmune conditions and infections such as hepatitis |
| Patient alert card | You carry it so any doctor knows you are on immunotherapy |
5. What to expect: step by step
| Step | What happens |
|---|---|
| 1. Blood tests | Usually a day or two before each treatment |
| 2. Review | A doctor, nurse or pharmacist checks for side effects |
| 3. Drip | A cannula is placed and the drug is given over about 30-60 minutes |
| 4. Short observation | Especially after the first doses |
| 5. Home | Most people go home the same day |
| 6. Repeat | Every 2-6 weeks depending on the drug |
| 7. Scans | Usually every 2-3 months |
Combination immunotherapy
When ipilimumab and nivolumab are given together, the first four doses are given every three weeks, followed by nivolumab alone. This combination is more effective in some cancers but causes more side effects.
6. Side effects and risks
Side effects of checkpoint inhibitors are called immune-related adverse events. They happen when activated immune cells attack healthy tissues. They can appear at any time, including months after treatment has stopped. A review of these effects notes that their exact cause is still not fully understood (Yin et al., 2023).
| Organ | Possible problem | Warning signs |
|---|---|---|
| Skin | Rash, itching, vitiligo | Itchy rash, blisters, loss of skin colour |
| Bowel | Colitis | Diarrhoea, blood in stool, tummy pain |
| Liver | Hepatitis | Yellow skin, dark urine; often found on blood tests |
| Lungs | Pneumonitis | New cough or breathlessness |
| Thyroid | Overactive or underactive thyroid | Tiredness, weight change, feeling hot or cold |
| Pituitary gland | Hypophysitis | Headache, tiredness, dizziness |
| Adrenal glands | Adrenal insufficiency | Weakness, low blood pressure, vomiting |
| Pancreas | Type 1 diabetes | Thirst, passing more urine, weight loss |
| Joints and muscles | Arthritis, myositis | Pain, stiffness, weakness |
| Heart | Myocarditis (rare but serious) | Chest pain, palpitations, breathlessness |
| Nerves | Neuropathy, myasthenia-like illness (rare) | Weakness, drooping eyelids, double vision |
How side effects are treated
| Severity | Usual approach |
|---|---|
| Mild | Continue treatment with symptom relief and monitoring |
| Moderate | Pause treatment; start steroids |
| Severe | Stop treatment; high-dose steroids, sometimes in hospital; other immune-suppressing drugs if needed |
| Hormone deficiencies | Lifelong hormone replacement, such as thyroxine or hydrocortisone |
A review of chronic side effects found that some problems, especially hormone deficiencies, arthritis and dry mouth, can persist for many months after treatment ends (Fletcher and Johnson, 2024).
When to call for help
Side effects of immunotherapy can look like ordinary illnesses, such as a stomach bug or a chest infection. Doctors who do not know you are on immunotherapy may not recognise them. Call your cancer team’s helpline straight away if you have diarrhoea several times a day, new breathlessness or cough, chest pain, severe headache, yellowing of the skin or sudden weakness. Show your alert card at any emergency department.
7. Results and outlook
| Study | Main finding |
|---|---|
| CheckMate 067, advanced melanoma (945 people) | Five-year survival was 52% with nivolumab plus ipilimumab, 44% with nivolumab alone and 26% with ipilimumab alone (Larkin et al., 2019) |
| KEYNOTE-024, lung cancer with high PD-L1 (305 people) | Five-year survival was about 32% with pembrolizumab versus about 16% with chemotherapy (Reck et al., 2021) |
These figures show a key feature of checkpoint inhibitors: a proportion of people have long-lasting responses, sometimes continuing after treatment stops. Before these drugs, long-term survival with advanced melanoma was rare.
Who responds?
Not everyone benefits. Response rates vary widely between cancers and between individuals, from under one in five to over half. Researchers are studying markers, gut bacteria and new combinations to help more people respond.
Quality of life
Many people find that checkpoint inhibitors are easier to live with than chemotherapy, with less sickness and no hair loss. In CheckMate 067, people treated with regimens containing nivolumab did not show a lasting decline in quality of life during or after treatment (Larkin et al., 2019). Even so, a minority develop severe side effects, so close monitoring remains essential.
Treatment before or after surgery
Checkpoint inhibitors are increasingly given before surgery (neoadjuvant) or after surgery (adjuvant) to lower the risk of cancer returning. This is now standard for some people with melanoma, lung, kidney, bladder and triple-negative breast cancers. Treatment in this setting is usually limited to about a year.
8. Recovery and aftercare
During and after treatment
| Tip | Why |
|---|---|
| Carry your alert card | Any doctor treating you needs to know about immunotherapy |
| Report new symptoms early | Most side effects are easier to treat when caught early |
| Do not stop steroids suddenly | Steroids must be reduced gradually |
| Keep up blood tests | Many side effects show up first in blood results |
| Get vaccinations as advised | Inactivated vaccines such as flu are usually recommended |
Follow-up after finishing
| Period | What to expect |
|---|---|
| First year | Scans and blood tests every few months |
| Years 2-5 | Less frequent scans |
| Long term | Ongoing hormone replacement if needed |
Fertility and pregnancy
Checkpoint inhibitors can cross the placenta and may harm a developing baby. Use effective contraception during treatment and for several months afterwards, as advised. Effects on long-term fertility are not yet well understood, so discuss egg or sperm storage before starting if you may want children in the future.
9. Alternatives
| Alternative | When it is considered |
|---|---|
| Targeted therapy | Cancers with driver mutations, such as BRAF, EGFR or ALK |
| Chemotherapy | Alone or combined with immunotherapy |
| Surgery or radiotherapy | Localised disease |
| CAR-T or other cell therapies | Some blood cancers |
| Clinical trials | New immunotherapy combinations |
| Best supportive care | When treatment is unlikely to help |
Looking after yourself
Gentle exercise, a balanced diet and good sleep can help with tiredness. Keep a note of any new symptoms, even small ones, and bring it to each appointment. Let your GP and dentist know that you are on immunotherapy.
10. Frequently asked questions
| Question | Answer |
|---|---|
| Will I lose my hair? | Hair loss is uncommon with checkpoint inhibitors alone |
| How quickly does it work? | Often over weeks to months |
| Can side effects start after treatment stops? | Yes, sometimes months later |
| Do steroids stop immunotherapy working? | Steroids for side effects do not appear to cancel the benefit in most people |
| Can I work during treatment? | Many people do |
| How long will I have treatment? | Often up to two years for advanced disease, or one year after surgery |
| What if I have an autoimmune disease? | It may still be possible with close monitoring; discuss with your team |
11. Questions to ask your care team
- Which checkpoint inhibitor do you recommend, and why?
- Will I have one drug or a combination?
- What side effects should I report immediately, and to whom?
- How long will treatment last?
- How will we know if it is working?
- What happens if I need steroids?
- Are there clinical trials I could join?
Resources
- Fletcher, K. and Johnson, D.B. (2024) ‘Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update’, Journal for ImmunoTherapy of Cancer, 12(7), e008591.
- Larkin, J. et al. (2019) ‘Five-year survival with combined nivolumab and ipilimumab in advanced melanoma’, New England Journal of Medicine, 381(16), pp. 1535-1546.
- Reck, M. et al. (2021) ‘Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or more’, Journal of Clinical Oncology, 39(21), pp. 2339-2349.
- Yin, Q. et al. (2023) ‘Immune-related adverse events of immune checkpoint inhibitors: a review’, Frontiers in Immunology, 14, 1167975.
- National Cancer Institute (2026) Immune Checkpoint Inhibitors. Available at: https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/checkpoint-inhibitors (Accessed: October 2026).
Prepared by the editorial team, October 2026.